Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE3. Research is primarily industry-sponsored.
8 publications have been identified in PubMed for microcystic lymphatic malformation. Research spans Case Report / Case Series (63%), Other (25%), and Clinical Trial Publication (13%).
Pulicari F (2026). [PMID: 42088154](https://pubmed.ncbi.nlm.nih.gov/42088154/). *Case Rep Dent*. [Case Report / Case Series]
Han T (2025). [PMID: 40660315](https://pubmed.ncbi.nlm.nih.gov/40660315/). *Head Face Med*. [Clinical Trial Publication]
Lei X (2025). [PMID: 40401862](https://pubmed.ncbi.nlm.nih.gov/40401862/). *Dermatol Pract Concept*. [Other]
Ghaleb M (2025). [PMID: 41725484](https://pubmed.ncbi.nlm.nih.gov/41725484/). *Dermatol Online J*. [Case Report / Case Series]
Loranger N (2025). [PMID: 40557740](https://pubmed.ncbi.nlm.nih.gov/40557740/). *Pediatr Dermatol*. [Case Report / Case Series]
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 12:49 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Xie C (2024). [PMID: 39866975](https://pubmed.ncbi.nlm.nih.gov/39866975/). *Cureus*. [Other]
Loeser JH (2024). [PMID: 38691122](https://pubmed.ncbi.nlm.nih.gov/38691122/). *Cardiovasc Intervent Radiol*. [Case Report / Case Series]
AI-curated news mentioning microcystic lymphatic malformation
Updated Feb 24, 2026
Palvella Therapeutics reports positive topline results from the Phase 3 SELVA study of QTORIN™ rapamycin for microcystic lymphatic malformations, meeting primary endpoints with a mean change of +2.13. This treatment addresses a significant unmet need for the over 30,000 patients in the U.S. with this condition.